Loading…
Loading…
EQUITY / NASDAQ · XNMS
20/20 Biolabs, Inc.
01 / RESEARCH
8 financial reports are available for research.
Start research ↗0.4365 USD · 0%
Observed: Sep 30, 2026, 8:00 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
09/30/2026 · 0.4365 USD · Volume 44,199
155 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Cash and cash equivalents | 4,546,140 USD | — | — |
| Gross profit | 304,727 USD | 163,264 USD | +86.65% |
| Net income | -1,506,343 USD | -840,933 USD | — |
| Operating profit | -1,244,223 USD | -845,671 USD | — |
| Revenue | 730,571 USD | 535,060 USD | +36.54% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD | 2025 / Year endConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 4,546,140 USD | — | — | 1,025,987 USD | 1,025,987 USD | — | — | — |
| Gross profitIncome statement | 304,727 USD | 367,611 USD | — | — | 604,541 USD | 163,264 USD | 329,058 USD | — |
| Net incomeIncome statement | -1,506,343 USD | -3,681,180 USD | -2,174,836 USD | — | -3,738,821 USD | -840,933 USD | -1,605,511 USD | -764,577 USD |
| Operating profitIncome statement | -1,244,223 USD | -2,687,579 USD | — | — | -3,330,871 USD | -845,671 USD | -1,617,852 USD | — |
| RevenueIncome statement | 730,571 USD | 1,083,946 USD | — | — | 2,045,133 USD | 535,060 USD | 1,088,880 USD | — |
| Total assetsBalance sheet | 6,123,185 USD | — | — | 4,137,357 USD | 4,137,357 USD | — | — | — |
| Total equityBalance sheet | 1,620,700 USD | — | 2,552,886 USD | -19,225 USD | -19,225 USD | 351,610 USD | — | 1,062,893 USD |
| Total liabilitiesBalance sheet | 2,963,877 USD | — | — | 4,156,582 USD | 4,156,582 USD | — | — | — |
| Financing cash flowCash flow statement | — | 5,427,427 USD | — | — | 1,161,698 USD | — | 262,338 USD | — |
| Investing cash flowCash flow statement | — | -12,854 USD | — | — | — | — | — | — |
| Operating cash flowCash flow statement | — | -1,894,420 USD | — | — | -1,919,720 USD | — | -1,022,398 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 03/31/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.